Clinical Trials · NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 7,101
- Start date
- Mar 2023
- Locations
- 633 sites, 25 countries
- Primary endpoint
- Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke